Ken Griffin Sensei Biotherapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sensei Biotherapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 15,366 shares of SNSE stock, worth $9,065. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,366
Previous 23,864
35.61%
Holding current value
$9,065
Previous $25,000
64.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SNSE
# of Institutions
25Shares Held
2.11MCall Options Held
0Put Options Held
0-
Ikarian Capital, LLC Dallas, TX650KShares$383,5000.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA619KShares$365,0660.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny224KShares$132,0330.0% of portfolio
-
Boothbay Fund Management, LLC New York, NY173KShares$101,9720.0% of portfolio
-
Geode Capital Management, LLC Boston, MA163KShares$96,2520.0% of portfolio
About Sensei Biotherapeutics, Inc.
- Ticker SNSE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,720,300
- Market Cap $18.1M
- Description
- Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune res...